Atara Biotherapeutics, Inc. (ATRA) Partner Resubmits Tab-cel BLA to FDA

Atara said partner Pierre Fabre resubmitted the tabelecleucel (tab-cel) BLA to the FDA with additional patients and longer follow-up from the ALLELE study. Atara expects to provide a revised anticipated PDUFA date when available.Material DetailsContext by AI AnalystThis is a regulatory re-filing st…